At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer (PROC); one of the most aggressive and treatment-refractory settings in gynecologic oncology.
The randomized study, recently published in the International Journal of Gynecological Cancer, reported a doubling of median overall survival, from approximately 13 months with chemotherapy alone to more than 25 months with the addition of Elenagen. The combination also reduced the risk of death by nearly 60%, without an observed increase in treatment-related toxicity.
While the survival figures are striking, the biological and practical implications of the findings may prove just as significant as the headline numbers.
The “Legacy Effect”: Insights from an Unplanned Interruption
One of the most unusual aspects of the trial was a non-medical interruption in drug supply that required all patients to discontinue Elenagen simultaneously, regardless of how long they had been receiving treatment.
Dr Vlad Gabai, Vice President of R&D at CureLab Oncology, emphasised that these interruptions were not linked to safety concerns.
“First and foremost, it must be articulated that no unplanned treatment interruptions were attributed to treatment-emergent adverse events, which is typically the cause in oncology trials. Instead, these synchronous interruptions occurred due to non-medical logistical reasons.”
The unexpected pause created an observational window. According to Gabai, during the first 12 months of therapy, longer exposure to Elenagen “strongly correlated with longer patient survival after the treatment was stopped.”
However, the incremental benefit appeared to taper beyond that period.
“The additional benefit of Elenagen appeared to diminish between the 12th and 24th months. Thus, although statistically positive, the extension of patient survival beyond 18 months of treatment was relatively minimal.”
This observation is shaping future trial planning. Gabai notes that upcoming U.S. and EU protocols will likely assume treatment durations of approximately 18–24 months, unless patients elect to discontinue.
He also stressed caution regarding mechanistic interpretation.
“There have been attempts to interpret this observation as indirect proof of CureLab’s mechanism of action hypothesis, specifically, that Elenagen remodels the tumor microenvironment to enhance the anti-cancer immune response. However, these conclusions are premature.”
Definitive confirmation would require serial tumor biopsies during and after treatment; procedures not performed in the trial for ethical and legal reasons.
“This valuable clinical observation cannot be used as definitive mechanism-of-action proof at this stage. CureLab maintains a rigorous commitment to evidence-based claims, avoiding speculative conclusions without direct confirmation.”
The CA-125 Signal: Why Higher-Risk Patients Responded More Strongly
The study also generated interest around patients with elevated CA-125 levels, traditionally associated with higher tumor burden and poorer prognosis.
Counterintuitively, these patients appeared to derive disproportionate benefit from the Elenagen combination.
Gabai offered several potential biological explanations.
“Elevated CA-125 is typically associated with more aggressive disease biology and systemic inflammation. Because Elenagen reduces chronic inflammation, its effect may be most pronounced in patients where inflammation is stronger and/or is a primary driver of disease progression.”
He also pointed to antigen load as a possible factor.
“Patients with elevated CA-125 levels often reflect a larger load of tumor-associated antigens. By increasing tumor-infiltrating lymphocytes and reducing intratumoral immunosuppression, Elenagen may provide a more robust benefit for patients whose tumors demonstrate a higher antigen load.”
